Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Regeneron Pharmaceuticals Inc (REGN) vs SoundHound AI Inc (SOUN) Price & Performance

Regeneron Pharmaceuticals IncTrade
SoundHound AI IncTrade

Price performance (Past 24H)

Key statistics

Regeneron Pharmaceuticals Inc vs SoundHound AI Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while SoundHound AI Inc trades at $6.5 (market cap $2.92B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 28.6× SoundHound AI Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals.

REGNSOUN
Market Cap
$83.43B$2.92B
Sector
HealthTechnology
52-Week High
$852.03$21.40
52-Week Low
$555.51$5.70
Enterprise Value
$78.14B$2.72B
Dividend Yield
0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

SoundHound AI Inc

SoundHound AI (SOUN) trades at $6.57, down 2.52% today, with mixed technical signals showing bearish moving averages but bullish oscillators. The company demonstrates strong revenue growth with Q2 2026 revenue up 45% year-over-year to $61.9 million, though it remains unprofitable with a -67.45% net income margin. Recent completion of the LivePerson acquisition creates a leading conversational AI platform with projected 2026 revenue of $230-260 million.

While analyst consensus remains bullish with 75% buy ratings and $8.50 price target (29% upside), significant risks include persistent losses, high valuation multiples (P/S 13.57), and negative cash flow projections for 2026. The stock's heavy short interest (nearly 40%) reflects market skepticism about profitability timeline despite strong top-line growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN

About SoundHound AI Inc

SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.

Read more on SOUN